MRI offers the possibility of personalized neoadjuvant chemotherapy for patients with HER2-positive breast cancer, but it may not be ready for prime time.
Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results